Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According...
Saved in:
| Main Authors: | Mauro Gori, Emilia D’Elia, Edoardo Sciatti, Michele Senni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-07-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2022.04 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment
by: Giulio Balestrieri, et al.
Published: (2024-04-01) -
Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
by: Brent Deschaine, et al.
Published: (2022-06-01) -
Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01) -
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
by: Vincenzo Castiglione, et al.
Published: (2023-06-01) -
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)